Wall Street brokerages expect Anavex Life Sciences Corp. (NASDAQ:AVXL) to report earnings per share of ($0.10) for the current quarter, according to Zacks. Zero analysts have issued estimates for Anavex Life Sciences’ earnings. Anavex Life Sciences reported earnings per share of ($0.18) in the same quarter last year, which would suggest a positive year over year growth rate of 44.4%. The company is scheduled to issue its next earnings report on Monday, December 11th.
On average, analysts expect that Anavex Life Sciences will report full year earnings of ($0.36) per share for the current financial year. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover Anavex Life Sciences.
AVXL has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of Anavex Life Sciences from a “hold” rating to a “buy” rating and set a $5.00 price target on the stock in a research note on Monday, September 18th. Maxim Group set a $15.00 price target on shares of Anavex Life Sciences and gave the company a “buy” rating in a research note on Monday, October 30th. ValuEngine lowered shares of Anavex Life Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, November 21st. Finally, Noble Financial restated a “buy” rating on shares of Anavex Life Sciences in a research note on Wednesday, August 9th.
A number of institutional investors have recently modified their holdings of AVXL. JPMorgan Chase & Co. acquired a new position in Anavex Life Sciences during the 1st quarter valued at approximately $105,000. American International Group Inc. increased its stake in Anavex Life Sciences by 7.1% during the 1st quarter. American International Group Inc. now owns 20,103 shares of the biotechnology company’s stock valued at $115,000 after purchasing an additional 1,329 shares in the last quarter. State of Wisconsin Investment Board acquired a new position in Anavex Life Sciences during the 2nd quarter valued at approximately $151,000. Alliancebernstein L.P. acquired a new position in Anavex Life Sciences during the 2nd quarter valued at approximately $158,000. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Anavex Life Sciences by 37.7% in the second quarter. The Manufacturers Life Insurance Company now owns 31,876 shares of the biotechnology company’s stock worth $169,000 after acquiring an additional 8,728 shares during the period. Institutional investors and hedge funds own 23.32% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Anavex Life Sciences Corp. (AVXL) Expected to Announce Earnings of -$0.10 Per Share” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/02/anavex-life-sciences-corp-avxl-expected-to-announce-earnings-of-0-10-per-share.html.
About Anavex Life Sciences
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.